Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Share:
Related LGND
Ligand Pharmaceuticals Q1 Adjusted Earnings Beat
Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017

In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $23.00 to $26.00.

In the report, Rivkind noted, “On March 14 the company announced its license and global supply agreement with Spectrum Pharmaceuticals on Captisol-enabled Melphalan for the treatment of multiple myeloma. Ligand received a $3M upfront payment and negotiated a healthy double-digit royalty (we estimate 20%) in addition to $50M in milestones that will be based on multiple regulatory and commercial events such as NDA acceptance, FDA approval, and launch. Spectrum is also taking over development costs, effective immediately.”

Ligand Pharmaceuticals closed on Friday at $23.27.

Latest Ratings for LGND

DateFirmActionFromTo
Apr 2016Stephens & Co.Initiates Coverage onOverweight
Mar 2016Roth CapitalMaintainsBuy
Mar 2016H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (LGND)

View Comments and Join the Discussion!